Literature DB >> 30408504

Reduction of nosocomial bloodstream infections and nosocomial vancomycin-resistant Enterococcus faecium on an intensive care unit after introduction of antiseptic octenidine-based bathing.

S Messler1, I Klare2, F Wappler3, G Werner2, U Ligges4, S G Sakka3, F Mattner5.   

Abstract

BACKGROUND: Vancomycin-resistant Enterococcus faecium (VRE) is emerging in German intensive care units (ICUs). On a 32-bed surgical ICU at a university hospital, increasing numbers of nosocomial cases occurred despite enforcement of hand hygiene and environmental disinfection. AIM: To introduce universal octenidine-based bathing in order to reduce the burden of VRE.
METHODS: Between January 2012 and March 2014, patients were screened for VRE on admission and twice weekly. Active surveillance was undertaken for VRE infections and colonizations, and for bloodstream infections (BSI) with any pathogen. Intervention in this before-after study comprised of standardized octenidine-based bathing. Distinct subgroups of VRE colonizations or infections were defined and used for statistical analysis of frequency, prevalence and incidence density.
FINDINGS: In the pre-intervention period (January 2012 to April 2013), the admission prevalence of VRE was 4/100 patients and the mean incidence density of nosocomial cases was 7.55/1000 patient-days (PD). Pulsed-field gel electrophoresis analysis revealed prevalence of three vanA and two vanB clusters. In the post-intervention period (August 2013 to March 2014), the admission prevalence of VRE was 2.41/100 patients and the mean incidence density of nosocomial cases was 2.61/1000 PD [P = 0.001 (pre- vs post-intervention)]. Thirteen nosocomial VRE infections were identified in the pre-intervention period, compared with one nosocomial VRE infection in the post-intervention period. Incidence densities of BSI pre- and post-intervention were 2.98 and 2.06/1000 PD (P = 0.15), respectively.
CONCLUSION: The epidemiology of emerging VRE appeared as a complex mix of admitted cases and transmissions in small clusters, challenging infection control measures. The implementation of universal octenidine-based bathing combined with a standardized washing regime led to a significant reduction in nosocomial VRE.
Copyright © 2018 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antiseptic bathing; Enterococcus spp.; Octenidine; VRE; Vancomycin resistance

Mesh:

Substances:

Year:  2018        PMID: 30408504     DOI: 10.1016/j.jhin.2018.10.023

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  5 in total

1.  Formulation of Chlorine-Dioxide-Releasing Nanofibers for Disinfection in Humid and CO2-Rich Environment.

Authors:  Barnabás Palcsó; Adrienn Kazsoki; Anna Herczegh; Ágoston Ghidán; Balázs Pinke; László Mészáros; Romána Zelkó
Journal:  Nanomaterials (Basel)       Date:  2022-04-27       Impact factor: 5.719

2.  Infection prevention requirements for the medical care of immunosuppressed patients: recommendations of the Commission for Hospital Hygiene and Infection Prevention (KRINKO) at the Robert Koch Institute.

Authors: 
Journal:  GMS Hyg Infect Control       Date:  2022-04-13

3.  The Characterization of Enterococcus Genus: Resistance Mechanisms and Inflammatory Bowel Disease.

Authors:  Michaela Růžičková; Monika Vítězová; Ivan Kushkevych
Journal:  Open Med (Wars)       Date:  2020-04-03

4. 

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2021-02       Impact factor: 1.513

5.  Evidence of the medical and economic benefits of implementing hygiene measures by a prevention link physician in trauma surgery: Study protocol for a biphasic multicenter prospective interventional pre-post cohort study using a structured intervention bundle development and tools of behavior change management.

Authors:  Meike M Neuwirth; Benedikt Marche; Christiane Kugler; Dominik Bures; Dirk Sauerland; Swetlana Herbrandt; Uwe Ligges; Frauke Mattner; Robin Otchwemah
Journal:  Contemp Clin Trials Commun       Date:  2021-07-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.